La vendita allo scoperto per COPT Defense Props dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di COPT Defense Props. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

COPT Defense Props (NYSE:CDP) Azioni, Report sulle vendite allo scoperto

COPT Defense

COPT Defense Props

COPT Defense Properties is a fully-integrated and self-managed real estate investment trust (REIT) focused on owning, operating and developing properties in locations proximate to, or sometimes containing, key U.S. Government (USG) defense installations and missions. Its tenants include the USG and their defense contractors, who are engaged in priority national security activities, and who generally require mission-critical and high security property enhancements. Its properties include 195 operating properties totaling approximately 22.4 million square feet comprised of 16.5 million square feet in 164 office properties and 5.9 million square feet in 31 single-tenant data center shells.

COPT Defense Properties Common Shares of Beneficial Interest

COPT Defense Properties

CANADIAN APT PRP R/E I/T by Canadian Apartment Properties Real Estate Investment Trust

Canadian Apartment Properties Real Estate Investment Trust

Small Cap Consumer Research analyst Eric Beder maintains Build-A-Bear Workshop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBW#NYSE">BBW</a>) with a Buy and raises the price target from $58 to $65.

News

Price Target

Analyst Ratings

Small Cap Consumer Research Maintains Buy on Build-A-Bear Workshop, Raises Price Target to $65

Baird analyst Daniel Moore reinstates Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) with a Neutral and announces $231 price target.

Initiation

Baird Reinstates Neutral on Union Pacific, Announces $231 Price Target

Offerings

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Inspira Technologies Increases Offering Price Of Ordinary Shares Under Sales Agreement Dated Mar. 14 From $1.9M To $7.1M

Galaxy Gaming, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GLXZ#OTC">GLXZ</a>), the world's leading independent developer and distributor of casino table games and technology, and Hasbro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>), a leading games, IP and toy entertainment company, today announced they have entered into a multi-year licensing agreement through which Galaxy Gaming will bring Hasbro's iconic games to casino table game pits.
Under the terms of the agreement, Galaxy Gaming will develop and distribute casino table games based on Hasbro's world-famous titles, including MONOPOLY, YAHTZEE, and BATTLESHIP. This partnership marries Galaxy Gaming's expertise in creating thrilling casino experiences with the nostalgic joy and distinctive excitement of Hasbro's beloved global brands. Casino patrons will soon enjoy the familiar rush of MONOPOLY, the suspense of rolling dice in YAHTZEE, and the explosive thrill of BATTLESHIP all reimagined for the table games pit.

Contracts

GLXZ

Galaxy Gaming And Hasbro Sign Multi-Year Licensing Deal To Bring MONOPOLY, YAHTZEE, And BATTLESHIP To Casino Table Games

Small Cap Consumer Research analyst Eric Beder reiterates a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) with a Buy and maintains $30 price target.

Reiteration

Small Cap Consumer Research Reiterates Buy on a.k.a. Brands Holding, Maintains $30 Price Target

Scandinavian Airlines (SAS) has entered into an agreement to acquire 45 Embraer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>, B3: EMBR3))) E195-E2 aircraft, with purchase rights for an additional 10 aircraft — the largest SAS jet order direct from a manufacturer since 1996. This milestone agreement supports SAS' long-term fleet renewal strategy, which is focused on increasing efficiency, reducing emissions, and unlocking future growth opportunities from its global hub in Copenhagen as well as across its Scandinavian and international network.
The first aircraft deliveries from Embraer are scheduled to begin in late 2027, with further deliveries extending over approximately four years. Excluding purchase rights, the value for the order is approximately US$4 billion.

Embraer-Empresa Brasileira De Aeronautica

SAS Orders 45 Embraer E195-E2 Jets With Option For 10 More In ~$4B Deal, First Deliveries Set For Late 2027

Baird analyst Daniel Moore reinstates Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) with a Outperform and announces $28 price target.

SNDR

Baird Reinstates Outperform on Schneider National, Announces $28 Price Target

Atai Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) and Beckley Psytech Limited jointly announced topline results from the eight-week, quadruple-masked, dose-finding core stage of the Phase 2b trial of a single dose of BPL-003 (intranasal mebufotenin (5-MeO-DMT) benzoate) in patients with <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">treatment-resistant depression </a>(TRD).
The study achieved its primary endpoint as well as all key secondary endpoints.
In June, the companies announced their plan to combine in an all-share transaction, subject to the pre-agreed <a href="https://www.benzinga.com/pressreleases/25/06/g45716633/atai-life-sciences-and-beckley-psytech-to-combine-creating-a-global-leader-in-psychedelic-mental-h">Phase 2b success criteria</a> for BPL-003 (mebufotenin benzoate).
The transaction is expected to close in the second half of 2025. 
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cannabis/25/05/45601096/ex-govt-foe-joins-trump-rfk-jr-s-hhs-to-lead-psychedelics-policy-what-it-means-for-investors" rel="noreferrer noopener">Ex-Gov&#8217;t Foe Joins Trump, RFK Jr.&#8217;s HHS To Lead Psychedelics Policy: What It Means For Investors</a>
<h2 class="wp-block-heading">Key Efficacy Findings:</h2>
At Day 29, a single 12 mg dose of BPL-003 demonstrated a statistically significant reduction in depressive symptoms, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with a mean decrease of 11.1 points from baseline compared to a 5.8 point reduction in the 0.3 mg <a href="https://www.benzinga.com/pressreleases/25/07/g46189490/atai-life-sciences-and-beckley-psytech-announce-positive-topline-results-from-the-phase-2b-study-o" target="_blank" rel="noreferrer noopener">comparator group (p = 0.0038)</a>.
For the key secondary efficacy endpoints, a single 8 mg dose of BPL-003 also showed significant improvement at Day 29, with a mean MADRS score reduction of 12.1 points (p = 0.0025 for change vs. the 0.3 mg control). The 8mg and 12mg of BPL-003 showed statistically significant improvements in MADRS scores as early as one day after dosing, with these effects generally maintained through Week 8.
The 8 mg and 12 mg doses of BPL-003 demonstrated equivalent efficacy, suggesting the 8 mg dose may be sufficient to achieve therapeutic benefit from a single dose.
The difference in MADRS scores between the 8 mg and 12 mg doses versus the 0.3 mg dose were statistically significant in both active arms from as early as Day 2, with mean MADRS reductions from baseline of 8.8 points in the 8 mg group and 8.9 points in the 12 mg group observed at that timepoint, compared to a reduction from baseline of 3.9 points in the 0.3 mg group.
These mean reductions from baseline increased to 11.1 points in the 8 mg group and 10.8 points in the 12 mg group at Day 8.
A durable effect was also observed for both higher doses, with the 8 mg group showing a mean reduction of 10.8 points from baseline at Day 57 and the 12 mg group showing a mean reduction of 10.2 points from baseline compared with the 0.3 mg group (5.2 point reduction).
<h2 class="wp-block-heading">Key Safety Findings:</h2>
Safety and efficacy results from this study support the selection of the 8 mg dose of BPL-003 for advancement into Phase 3 clinical studies.
More than 99% of treatment-emergent adverse events (TEAEs) were mild or moderate; there were no drug-related serious adverse events (SAEs).
Dose-related increases in administration site discomfort, nausea, headache, blood pressure, and anxiety suggest that the 8mg dose was better tolerated than the 12mg dose.
No participants in the 8 mg or 12 mg arms had any instance of treatment-emergent suicidal intent or behaviour, indicating no suicide-related safety signal observed to date.
Follow-up in the study&#8217;s eight-week open-label extension (OLE) stage is ongoing.
The OLE study evaluates the safety and efficacy of a second 12 mg BPL-003 administered to patients eight weeks after dosing in the core study. Data from the OLE study is expected in the third quarter of 2025 and will provide additional insights into the safety and tolerability of repeat dosing, as well as the durability of BPL-003&#8217;s antidepressant effect.
Concurrently, on Tuesday, Atai Life Sciences announced the private placement of 18.3 million shares with a nominal value of €0.10 (approximately $0.11) and pre-funded warrants to purchase 4.6 million shares, with approximately <a href="https://www.benzinga.com/pressreleases/25/07/g46189588/atai-life-sciences-announces-50-million-private-placement-financing" target="_blank" rel="noreferrer noopener">$50 million in gross proceeds</a>.
Price Action: ATAI stock was up 28.3% at $2.81 during the premarket session at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/legal/25/07/46193030/johnson-johnsons-drug-discount-plan-gets-thrown-out-in-court" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s Drug Discount Plan Gets Thrown Out In Court</a></li>
</ul>
Photo: Shutterstock

Cannabis

Psychedelics

Health Care

Movers

Trading Ideas

General

ATAI

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

RBC Capital analyst Mike Dahl maintains GMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) with a Sector Perform and raises the price target from $95.2 to $110.

RBC Capital Maintains Sector Perform on GMS, Raises Price Target to $110

WIIM

DDC Enterprise shares are trading higher after the company announced the closing of its $528 million capital financing round with Anson Funds to advance its Bitcoin treasury strategy.

Baird analyst Daniel Moore reinstates Ryder System (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>) with a Outperform and announces $186 price target.

Baird Reinstates Outperform on Ryder System, Announces $186 Price Target

Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) (the &quot;Company&quot;), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $6 million prior to deducting underwriting commissions and offering expenses.
The offering is comprised of (i) 865,000 Class A Units with each Class A Unit consisting of (a) one share of common stock and (b) one common warrant to purchase one share of common stock (the &quot;Common Warrants&quot;), and (ii) 335,000 Class B Units with each Class B Unit consisting of (a) one pre-funded common stock purchase warrant to purchase one share of common stock (&quot;Pre-funded Warrants&quot;) and (b) one Common Warrant. The price per Class A Unit is $5.00 and the price per Class B Unit is $4.99999 (collectively, the &quot;Offering&quot;). The Common Warrants will have an exercise price of $5.25 per share, will be exercisable upon issuance, and have a term expiring five years from issuance.
Ladenburg Thalmann &amp; Co. Inc. is acting as sole bookrunning manager in connection with this Offering.

CLRB

Cellectar Biosciences Prices $6M Offering Of 865K Class A Units And 335K Class B Units with Warrants Exercisable At $5.25; Price Per Class A Unit Is $5.00 And The Price Per Class B Unit Is $4.99999

RBC Capital analyst Christopher Dendrinos maintains First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Outperform and raises the price target from $188 to $200.

FSLR

RBC Capital Maintains Outperform on First Solar, Raises Price Target to $200

Wells Fargo analyst Joseph O'Dea maintains Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) with a Equal-Weight and lowers the price target from $72 to $55.

Wells Fargo Maintains Equal-Weight on Fortive, Lowers Price Target to $55

Baird analyst Daniel Moore reinstates Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) with a Neutral and announces $164 price target.

ODFL

Baird Reinstates Neutral on Old Dominion Freight Line, Announces $164 Price Target

IGMS

IGM Biosciences shares are trading higher after the company announced it will be acquired by Concentra Biosciences for $1.247 per share.

Baird analyst Daniel Moore reinstates Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) with a Neutral and announces $255 price target.

Baird Reinstates Neutral on Norfolk Southern, Announces $255 Price Target

New name and stock symbol highlight strategic commitment to TAO, the leading AI cryptocurrency
NEW YORK, July 1, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOX#NASDAQ">TAOX</a>) (the "Company"), formerly Synaptogenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>), announces that its common stock, listed on the Nasdaq Capital Market, begins trading under the new ticker symbol, "TAOX," effective at the market open today, July 1, 2025. The new name and trading symbol coincides with the Company's previously announced digital asset treasury strategy focused exclusively on acquiring and staking TAO cryptocurrency.

SNPX

TAOX

TAO Synergies, Formerly Synaptogenix, Begins Trading Under New Ticker Symbol "TAOX" On Nasdaq Capital Market

OBLG

Oblong shares are trading higher after the company acquired 5,025 $TAO tokens for $1.65 million.

$1.65M deployed into $TAO from new capital raised in June 2025
5,025 tokens acquired and fully staked into the Bittensor ecosystem
Oblong, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>, "Oblong" or the "Company"))), today announced it has strengthened its decentralized AI treasury strategy by acquiring 5,025 $TAO tokens for $1.65 million, using proceeds from its recent $7.5 million financing. This follows the Company's June 6, 2025, announcement to pivot toward decentralized AI, with the purchase of $TAO at an average price of $328.38 per token reinforcing its commitment to innovative, high-growth assets for investors.
The $TAO investment underscores Oblong's focus on Bittensor's decentralized AI protocol, which fosters global collaboration in machine learning. By staking all 5,025 tokens in the Bittensor network, the Company is actively supporting the ecosystem while enhancing its treasury's performance. "Oblong's initial $TAO purchase fulfills its commitment to a forward-thinking reserve while exploring Bittensor ecosystem partnerships, as $TAO's innovative AI approach offers compelling exposure to a rapidly growing sector," said Peter Holst, CEO of Oblong.
This is the first of several planned investments in the Bittensor ecosystem, with Oblong evaluating additional $TAO purchases on a weekly basis. The Company is also exploring partnerships within the Bittensor ecosystem to potentially develop technology offerings, further aligning its operational and treasury strategies. Transparent updates on treasury performance, including staking yields and token holdings, will be provided in Oblong's Q2 2025 earnings results and at upcoming investor conferences.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$TAO

Oblong Invests $1.65M To Acquire And Stake 5,025 $TAO Tokens, Advancing Decentralized AI Strategy In Bittensor Ecosystem

Press Releases

COPT Defense Reports Strong Full Year 2024 Results

COPT Defense Establishes 2025 Guidance

COPT Defense Increases Quarterly Dividend by 3.4%

COPT Defense to Present at Citi's 2025 Global Property CEO Conference

COPT Defense Executes 48,000 SF Lease with a Top 10 U.S. Defense Contractor at Franklin Center in Columbia Gateway

COPT Defense Provides Conference Call Details to Discuss 1Q 2025 Results

COPT Defense Executes Two Investment Leases in Redstone Gateway Totaling 55,000 SF, Bringing Total Portfolio Year-to-Date Investment Leasing to 103,000 SF

Comments

COPT Defense Props

Vendite allo scoperto

COPT Defense Props (NYSE:CDP) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO